Format

Send to

Choose Destination
Expert Opin Emerg Drugs. 2011 Mar;16(1):85-103. doi: 10.1517/14728214.2011.531698.

Current status of agents active against the T315I chronic myeloid leukemia phenotype.

Author information

1
HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Ireland.

Abstract

INTRODUCTION:

T315I is a genetic mutation of the Bcr-Abl tyrosine kinase, the pathogenetic abnormality in chronic myeloid leukemia (CML). It accounts for 10 ? 15% of clinically relevant CML mutations. Licensed tyrosine kinase inhibitors are ineffective against this mutation and its development reduces life expectancy of CML in chronic phase from 10 years to just 22 months. Extensive work is ongoing to establish the most effective therapy to overcome this mutation, including the development of novel specific agents and also re-examination of established therapies.

AREAS COVERED:

This review examines the agents in development, dividing them into Bcr-Abl-dependant and -independent groups. It looks at the progress of this research, updating the reader on the status of agents previously reported and introducing emerging therapeutic possibilities only recently announced.

EXPERT OPINION:

Development of the T315I mutation is a devastating event for some patients with CML. There are potential therapeutic agents at all stages of the drug development cycle to target this patient subpopulation. Clinical activity has been demonstrated and a number of agents are on the cusp of being licensed and available for use.

PMID:
21352071
DOI:
10.1517/14728214.2011.531698
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center